We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 2318 for:    melanoma

Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01573494
Recruitment Status : Completed
First Posted : April 9, 2012
Last Update Posted : June 26, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Circulating tumor cells (CTC) are the subject of increasing interest in clinical oncology as a prognostic factor and predictor of therapeutic response. The detection of CTC by immunomagnetic method has proved its reliability and its usefulness for monitoring breast cancer, colon and prostate in the metastatic and immunomagnetic detection system (CellSearch, Veridex LLC) was approved by the FDA in these indications. However, to date there is no reliable method to detect CTCs in melanoma (CMC). Studies based on PCR amplification of mRNA by reverse specific melanoma is disappointing. Recently, a new detection system of CMC immunomagnetic was presented (CellSearch, Veridex LLC, United States). This system has the advantage of combining immunomagnetic selection step and a step of identifying by immunofluorescence. A preclinical study on serial dilutions of melanoma cells has shown encouraging results. The investigators propose a prospective study of the CellSearch system in patients with melanoma.

Primary objective: To determine the effect of treatment on the number of circulating melanoma cells in patients with metastatic melanoma.

Secondary objectives:

  • determine the percentage of patients with metastatic melanoma with melanoma cells circulating
  • seek a relationship between the number of circulating melanoma cells and prognosis in patients with metastatic melanoma
  • seek a relationship between the change in the number of circulating melanoma cells before / after treatment and tumor response in patients with metastatic melanoma

Condition or disease Intervention/treatment
Melanoma Other: Sampling of blood

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma.
Study Start Date : May 2012
Primary Completion Date : November 2013
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Metastatic melanoma patients
Sampling of blood before and after chemotherapy
Other: Sampling of blood
7,5 ml of blood


Outcome Measures

Primary Outcome Measures :
  1. Measuring the number of circulating melanoma cells/ml in blood [ Time Frame: baseline and 3 months ]
    Measuring the number of circulating melanoma cells/ml in the peripheral blood by the test before and after treatment CellSearch.


Secondary Outcome Measures :
  1. number of patients who test positive detection of circulating melanoma cells measured in peripheral blood with the CellSearch test [ Time Frame: 3 months ]
    Calculating the number of patients who test positive detection of circulating melanoma cells measured in peripheral blood with the CellSearch test before and after treatment.

  2. Difference in survival [ Time Frame: baseline and 6 months ]
    Difference in survival between patients depending on the number of circulating melanoma cells/ml before treatment, according to Kaplan-Meier method.

  3. Difference in tumor response [ Time Frame: 6 months ]
    Difference in tumor response between patients according to the variation of circulating melanoma cells/ml before and after treatment.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients > or = 18 years
  • Patients with advanced melanoma stage IIIC (unresectable) or stage IV
  • Patient not treated or not responding to chemotherapy with chemotherapy session last> 1 month
  • Patients who signed informed consent
  • Patients presenting no socio-economic, psychological, familial or geographical allow proper understanding of the information leaflet of the protocol or the regular monitoring in the department of dermatology
  • Patients with a life expectancy greater than 3 months
  • Patients with melanoma measurable by RECIST version 1.1
  • Patients with venous good for venipuncture

Exclusion Criteria:

  • Patients with contraindication for treatment with chemotherapy or V600E BRAF inhibitor or ipilimumab or have conditions concomitant heavy may interfere with the treatment of metastatic melanoma
  • Pregnant women or nursing
  • People vulnerable detainees, adults under guardianship or curatorship, minors.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01573494


Locations
France
CHU de Nice
Nice, France, 06202
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Investigators
Study Director: Damien GIACCHERO, PH CHU de Nice
More Information

Responsible Party: Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier: NCT01573494     History of Changes
Other Study ID Numbers: 11-AOI-04
First Posted: April 9, 2012    Key Record Dates
Last Update Posted: June 26, 2014
Last Verified: June 2014

Keywords provided by Centre Hospitalier Universitaire de Nice:
Cancer
Melanoma
Circulating Tumor Cells

Additional relevant MeSH terms:
Melanoma
Nevi and Melanomas
Neoplastic Cells, Circulating
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes